{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T12:17:13Z","timestamp":1783513033837,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-026-03352-x","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:39:05Z","timestamp":1783510745000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Practice patterns of DOAC high-intensity period following parenteral lead-in treatment for venous thromboembolism"],"prefix":"10.1007","author":[{"given":"Tahsin","family":"Najmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Kaatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"DeCamillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Edwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Haymart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Froehlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey D.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"issue":"Supplement 1","key":"3352_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood-2020-136867","volume":"136","author":"A Gupta","year":"2020","unstructured":"Gupta A, Day J, Streiff M, Takemoto C, Jung K, Abro C, Gehrie E, Bloch E, Tobian A, Goel R (2020) Mortality and Associated Comorbidities Among Patients Hospitalized for Deep Vein Thrombosis and Pulmonary Embolism in the United States: Results from a Nationally Representative Database. Blood 136(Supplement 1):39\u201340. https:\/\/doi.org\/10.1182\/blood-2020-136867","journal-title":"Blood"},{"issue":"26","key":"3352_CR2","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","volume":"363","author":"R Bauersachs","year":"2010","unstructured":"Bauersachs R, Berkowitz SD, Brenner B et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499\u20132510. https:\/\/doi.org\/10.1056\/NEJMoa1007903","journal-title":"N Engl J Med"},{"issue":"9","key":"3352_CR3","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799\u2013808. https:\/\/doi.org\/10.1056\/NEJMoa1302507","journal-title":"N Engl J Med"},{"key":"3352_CR4","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/jth.12485","volume":"12","author":"T Van der Hulle","year":"2014","unstructured":"Van der Hulle T, Kooiman P, den Exter PL, Dekkers OM, Klok FA, Huisman MV (2014) Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systemic review and meta-analysis. J Thromb Haemost 12:320\u2013328. https:\/\/doi.org\/10.1111\/jth.12485","journal-title":"J Thromb Haemost"},{"key":"3352_CR5","unstructured":"U.S. Food and Drug Administration. Eliquis (apixaban) prescribing information. U.S. Department of Health and Human Services (2012) Accessed December 10, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202155s000lbl.pdf"},{"key":"3352_CR6","unstructured":"U.S. Food and Drug Administration. Xarelto (rivaroxaban) prescribing information. U.S. Department of Health and Human Services (2021) Accessed December 10, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215859s000lbl.pdf"},{"key":"3352_CR7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s11239-022-02641-5","volume":"54","author":"M Williams","year":"2022","unstructured":"Williams M, Ahuja T, Raco V et al (2022) Real world prescribing practices of apixaban or rivaroxaban lead-in doses for the treatment of venous thromboembolism in hospitalized patients. J Thromb Thrombolysis 54:219\u2013229. https:\/\/doi.org\/10.1007\/s11239-022-02641-5","journal-title":"J Thromb Thrombolysis"},{"key":"3352_CR8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/jcph.2350","volume":"64","author":"SS Cho","year":"2024","unstructured":"Cho SS, Yin E, Dalton K (2024) Evaluation of lead-in direct oral anticoagulant prescribing practices in newly diagnosed venous thromboembolism. J Clin Pharmacol 64:182\u2013188","journal-title":"J Clin Pharmacol"},{"key":"3352_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2147\/IJGM.S392505","volume":"16","author":"GB Korayem","year":"2023","unstructured":"Korayem GB, Alshaya OA, Alnajjar N, Alawad A, Alotaibi R, Bin Sheraim N et al (2023) Real-world evaluation of the safety and effectiveness of apixaban and rivaroxaban lead-in dosing compared to parenteral lead-in dosing in the treatment of venous thromboembolism: A multi-center retrospective cohort study. Int J Gen Med 16:129\u2013140","journal-title":"Int J Gen Med"},{"key":"3352_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3390\/jcm12010199","volume":"12","author":"OA Alshaya","year":"2022","unstructured":"Alshaya OA, Korayem GB, Al Yami MS, Qudayr AH, Althewaibi S, Fetyani L et al (2022) Comparative effectiveness of apixaban and rivaroxaban lead-in dosing in VTE treatment: Observational multicenter real-world study. J Clin Med 12:199","journal-title":"J Clin Med"},{"key":"3352_CR11","doi-asserted-by":"publisher","DOI":"10.1177\/08971900251313649","author":"L Jackson","year":"2025","unstructured":"Jackson L, Gillion A, Marler J (2025) Impact of apixaban lead-in therapy duration after parenteral anticoagulation on bleeding in patients treated for venous thromboembolism. J Pharm Pract. https:\/\/doi.org\/10.1177\/08971900251313649","journal-title":"J Pharm Pract"},{"issue":"6","key":"3352_CR12","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1007\/s11096-025-01993-1","volume":"47","author":"J Kim","year":"2025","unstructured":"Kim J, Heybati K, Thompson E, Shiue H (2025) Does direct oral anticoagulant lead-in dosing following initial parenteral therapy affect clinical outcomes in acute venous thromboembolism? A retrospective cohort study. Int J Clin Pharm 47(6):1885\u20131893. https:\/\/doi.org\/10.1007\/s11096-025-01993-1 Epub 2025 Aug 23","journal-title":"Int J Clin Pharm"},{"issue":"12","key":"3352_CR13","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1182\/blood.2020005819","volume":"136","author":"F Mulder","year":"2020","unstructured":"Mulder F, Bosch F, Young A, Marshall A, McBane R, Zemla T, Carrier M, Kamphuisen P, Bossuyt P, B\u00fcller H, Weitz J, Middeldorp S, van Es N (2020) Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood 136(12):1433\u20131441. https:\/\/doi.org\/10.1182\/blood.2020005819","journal-title":"Blood"},{"key":"3352_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ahj.2017.09.006","volume":"195","author":"CM Yong","year":"2018","unstructured":"Yong CM, Liu Y, Apruzzese P, Doros G, Cannon CP, Maddox TM, Gehi A, Hsu JC, Lubitz SA, Virani S, Turakhia MP, ACC PINNACLE Investigators (2018) Association of insurance type with receipt of oral anticoagulation in insured patients with atrial fibrillation: A report from the American College of Cardiology NCDR PINNACLE registry. Am Heart J 195:50\u201359. https:\/\/doi.org\/10.1016\/j.ahj.2017.09.006. PMID: 29224646","journal-title":"Am Heart J"},{"issue":"5","key":"3352_CR15","doi-asserted-by":"publisher","first-page":"e002721","DOI":"10.1161\/JAHA.115.002721","volume":"5","author":"EC O\u2019Brien","year":"2016","unstructured":"O\u2019Brien EC, Kim S, Thomas L, Fonarow GC, Kowey PR, Mahaffey KW, Gersh BJ, Piccini JP, Peterson ED (2016) Clinical characteristics, oral anticoagulation patterns, and outcomes of Medicaid patients with atrial fibrillation: Insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) registry. J Am Heart Assoc 5(5):e002721. https:\/\/doi.org\/10.1161\/JAHA.115.002721 PMID: 27146448; PMCID: PMC4889165","journal-title":"J Am Heart Assoc"},{"key":"3352_CR16","doi-asserted-by":"publisher","first-page":"4523","DOI":"10.1007\/s12325-023-02620-z","volume":"40","author":"T Salam","year":"2023","unstructured":"Salam T, Desai U, Lefebvre P et al (2023) Unintended Consequences of Increased Out-of-Pocket Costs During Medicare Coverage Gap on Anticoagulant Discontinuation and Stroke. Adv Ther 40:4523\u20134544. https:\/\/doi.org\/10.1007\/s12325-023-02620-z","journal-title":"Adv Ther"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03352-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-026-03352-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03352-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:39:06Z","timestamp":1783510746000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-026-03352-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":16,"alternative-id":["3352"],"URL":"https:\/\/doi.org\/10.1007\/s11239-026-03352-x","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"8 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.K. reports receiving research funding from Inari, Regeneron and Perosphere. He reports consulting for Perosphere, Regeneron, Bayer, Anthos and Gilead. He is a member of the Scientific Advisory Board for the National Blood Clot Alliance. G.D.B reports consulting for Pfizer, Bristol Myer Squibb, Janssen, Boston Scientific, and Abbott Vascular. He serves on the Board of Directors for Anticoagulation Forum. Authors not named here have disclosed no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}